Academic Journal
Proton pump inhibitor use and long-term outcomes in SSc: a real-life analysis from the EUSTAR database.
| Τίτλος: | Proton pump inhibitor use and long-term outcomes in SSc: a real-life analysis from the EUSTAR database. |
|---|---|
| Συγγραφείς: | Bonomi F; Department of Internal Medicine, University Hospital Careggi, Florence, Italy., Bandini G; Department of Internal Medicine, University Hospital Careggi, Florence, Italy., Campochiaro C; Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy., De Silvestri V; Department of Internal Medicine, University Hospital Careggi, Florence, Italy., Agachi S; Discipline of Rheumatology and Nephrology, Department of Internal Medicine, Nicolae Testemițanu State University of Medicine and Pharmacy, Chisinau, Moldova., Bergmann C; Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), FAU Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany., Distler O; Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland., Granel B; Department of Internal Medicine, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France., Henes J; Center for Interdisciplinary Rheumatology, Immunology and Autoimmune Diseases (INDIRA) and Department for Internal Medicine II (Hematology, Oncology, Rheumatology and Clinical Immunology), University Hospital Tuebingen, Tuebingen, Germany., Iannone F; Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), Polyclinic Hospital, University of Bari, Bari, Italy., Idolazzi L; Rheumatology Section, Department of Medicine, University of Verona, Verona, Italy., Kerzberg E; Departamento de Medicina Interna, Hospital General de Agudos J.M Ramos Mejía, Buenos Aires, Argentina., Naffaa ME; The Rheumatology Unit, Galilee Medical Center, Nahariyya, Israel.; The Azrieli's Faculty of Medicine, Bar-Ilan University, Safed, Israel., Poormoghim H; Iran University of Medical Sciences, Tehran, Iran., Radic M; Department of Internal Medicine, Division of Rheumatology, Allergology and Clinical Immunology, Center of Excellence for Systemic Sclerosis in Croatia, University Hospital of Split, Split, Croatia.; Internal Medicine Department, School of Medicine, University of Split, Split, Croatia., Truchetet ME; ImmunoConcEpT, UMR 5164, University Bordeaux, CNRS, Bordeaux, France.; CHU de Bordeaux, FHU ACRONIM, Centre national de référence des maladies auto-immunes et systémiques rares Est/Sud-Ouest (RESO), Bordeaux, France., Bellando Randone S; Department of Experimental and Clinical Medicine, Division of Rheumatology, Careggi University Hospital, University of Florence, Florence, Italy., Matucci Cerinic M; Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milan, Italy.; Vita Salute San Raffaele University, Milano, Italy.; Inflammation Fibrosis and Ageing Initiative, (INFLAGE), Division of Genetics and Cell Biology, IRCCS San Raffaele Scientific Institute, Milano, Italy., McMahan ZH; Division of Rheumatology, UTHealth Houston, Houston, TX, USA., Hughes M; Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.; Northern Care Alliance NHS Foundation Trust, Salford Care Organisation, Salford, UK.; NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, UK. |
| Συλλογικό Έργο: | EUSTAR Group |
| Πηγή: | Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2026 Oct 01; Vol. 65 (10). |
| Τύπος έκδοσης: | Journal Article; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100883501 Publication Model: Print Cited Medium: Internet ISSN: 1462-0332 (Electronic) Linking ISSN: 14620324 NLM ISO Abbreviation: Rheumatology (Oxford) Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Oxford, UK : Avenel, N.J. : Oxford University Press ; Distributed by Mercury International, c1999- |
| Ιατρικοί όροι (MeSH): | Proton Pump Inhibitors*/therapeutic use , Scleroderma, Systemic*/mortality , Scleroderma, Systemic*/complications , Scleroderma, Systemic*/drug therapy , Lung Diseases, Interstitial*/etiology , Lung Diseases, Interstitial*/mortality , Lung Diseases, Interstitial*/physiopathology, Humans ; Female ; Disease Progression ; Middle Aged ; Male ; Registries ; Aged |
| Περίληψη: | Objectives: To investigate the association between proton pump inhibitor (PPI) use, all-cause mortality and interstitial lung disease (ILD) progression in SSc. Methods: SSc patients enrolled in the EUSTAR registry with at least two clinical visits were included (EUSTAR CP141). PPI exposure was modelled as a time-varying variable. Inverse probability of treatment weighting (IPTW) based on propensity scores was applied to address confounding by indication. All-cause mortality was analysed using IPTW-weighted time-varying Cox models. ILD progression was assessed using functional endpoints (FVC decline ≥10% and ≥5%; DLCO decline ≥10%). Restricted mean survival time (RMST) was used to quantify absolute effects. Sensitivity analyses included a 6-month lag time. Results: Out of 10 660 patients enrolled, 8637 (81.0%) were exposed to PPIs during a mean follow-up of 5.7 ± 4.3 years. They exhibited a more severe multisystem disease phenotype, including greater gastrointestinal, pulmonary and vascular involvement. After adjustment, PPI exposure was associated with higher all-cause mortality (HR 1.88, 95% CI 1.40-2.54), although the RMST difference at 5 years was minimal. As cause-specific mortality was unavailable, this association might reflect underlying disease severity rather than a direct drug effect. The use of PPI was not associated with a reduced risk of clinically meaningful FVC decline, while a modest attenuation of DLCO decline was observed, and absolute progression-free differences were limited. Conclusions: PPI is commonly used in SSc characterized by a more severe multisystem phenotype. Only a marginal attenuation of ILD progression is observed, although absolute effects were small. These findings favour the generalized use of PPIs for symptomatic gastroesophageal reflux in SSc. (© The Author(s) 2026. Published by Oxford University Press on behalf of the British Society for Rheumatology.) |
| References: | J Gastroenterol. 2024 Mar;59(3):179-186. (PMID: 38252140) Rheumatology (Oxford). 2023 Sep 1;62(9):3067-3074. (PMID: 36708008) Eur J Clin Pharmacol. 2024 Mar;80(3):367-382. (PMID: 38147074) Sci Rep. 2020 Jan 21;10(1):769. (PMID: 31964957) Rheumatology (Oxford). 2026 Jan 8;65(1):. (PMID: 40911437) Expert Opin Pharmacother. 2025 Apr;26(5):551-566. (PMID: 39981635) Semin Arthritis Rheum. 2010 Dec;40(3):241-9. (PMID: 20494406) Arthritis Res Ther. 2024 Jun 25;26(1):124. (PMID: 38918847) Rheumatology (Oxford). 2021 Feb 1;60(2):849-854. (PMID: 32829395) Pharmacol Res Perspect. 2020 Oct;8(5):e00651. (PMID: 32996701) Rheumatology (Oxford). 2025 Jun 1;64(6):3266-3279. (PMID: 39909554) Chonnam Med J. 2023 May;59(2):115-127. (PMID: 37303818) Eur Respir J. 2020 May 14;55(5):. (PMID: 32079645) Nat Rev Rheumatol. 2023 Mar;19(3):166-181. (PMID: 36747090) Lancet Rheumatol. 2022 Nov;4(11):e795-e803. (PMID: 37936680) Rheumatology (Oxford). 2025 May 1;64(5):3074-3079. (PMID: 39250735) Front Med (Lausanne). 2022 Jan 27;8:807982. (PMID: 35155484) Rheumatology (Oxford). 2025 Nov 1;64(11):5892-5898. (PMID: 40457812) Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. (PMID: 35486072) Ann Rheum Dis. 2021 Feb;80(2):219-227. (PMID: 32988845) Ann Rheum Dis. 2017 Nov;76(11):1897-1905. (PMID: 28835464) Rheumatology (Oxford). 2026 Feb 04;65(2):. (PMID: 41649461) Ann Rheum Dis. 2025 Jan;84(1):29-40. (PMID: 39874231) Clin Rheumatol. 2025 Oct;44(10):4061-4070. (PMID: 40936007) Rheumatology (Oxford). 2025 May 1;64(5):2766-2774. (PMID: 39213328) RMD Open. 2024 Sep 5;10(3):. (PMID: 39242112) Neurogastroenterol Motil. 2018 Feb;30(2):. (PMID: 29110377) Gastroenterology. 2017 Mar;152(4):706-715. (PMID: 28257716) ACR Open Rheumatol. 2025 Jan;7(1):e11796. (PMID: 39854163) Curr Opin Rheumatol. 2019 Nov;31(6):561-568. (PMID: 31389815) Arthritis Care Res (Hoboken). 2023 Aug;75(8):1715-1724. (PMID: 36576023) Ann Rheum Dis. 2013 Nov;72(11):1747-55. (PMID: 24092682) Semin Arthritis Rheum. 2024 Aug;67:152419. (PMID: 38430623) RMD Open. 2023 Nov;9(4):. (PMID: 37940340) Arthritis Care Res (Hoboken). 2024 May;76(5):608-615. (PMID: 38111164) |
| Contributed Indexing: | Investigator: UA Walker; R Bečvář; E Siegert; Y Allanore; C Montecucco; M Inanc; P Carreira; G Kumánovics; M Iudici; P Kotyla; E Zanatta; G Moroncini; P Airò; A Balbir-Gurman; A Iagnocco; J Mitrovic; C Denton; M Vonk; G Bajocchi; T Santiago; M De Santis; D Launay; V Riccieri; A Balanescu; AM Gheorghiu; V Smith; A Corrado; M Mogensen; M Vanthuyne; JJA Sancho; B Anić; C de Souza Müller; A Cauli; K Solanki; E Soliman; E Rosato; B Maurer; S Blaise; P Senet; E Chatelus; F Del Galdo; I Castellví; M Limonta; A Marcoccia; I Koetter; V Hsu; D Khanna; C Teles; Y Levy; E Rezus; DB de Araujo; G Cuomo; P Sfikakis; AM Ramazan; J de Vries-Bouwstra; A Lescoat; J Spierings; F Atzeni; M Kuwana; M Martin; AG Del-Castillo; M Parvu; G Boleto; N Del Papa; E Selvi; M Mosca; U Gerth; DT Karadag; A Batalov; C Maglio; M Retuerto; M Hinchcliff; S Tharwat; AC Cordeiro; F Benvenuti; AH Györfi; LML Nunez; R De Angelis; A Brigante; Y El Miedany; A de Paulis; C Derk; L Zhang; B Batko; IC Sole; A Lewandowska-Polak; B Atienza-Mateo; T Duruöz; S Colak; JV Guzmán; C Mora-Trujillo; B Lindner; MS Chimenti; SA El-Bakry; V Ortiz-Santamaria; J Rojas-Serran; F Alibaz-Oner; ED Ersözlü; RM Louis; M Liang; M Triggiani; A Karamanakos; B Dumitru; L Carter; B André; G Murdaca; PC Garcia; T Simopoulou; F Cacciapaglia; T Ramineni; G Mansuco; J Calizaya-Estrada; GG Maghraby; M Erdogan; WN Huang; G Sequeira; G Pellegrino; C Vaz; M Buch; J Kosałka-Węgiel Keywords: SSc; interstitial lung disease; proton pump inhibitor; scleroderma |
| Substance Nomenclature: | 0 (Proton Pump Inhibitors) |
| Entry Date(s): | Date Created: 20260918 Date Completed: 20261005 Latest Revision: 20261007 |
| Update Code: | 20261007 |
| PubMed Central ID: | PMC13637600 |
| DOI: | 10.1093/rheumatology/keag521 |
| PMID: | 42760267 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1462-0332 |
|---|---|
| DOI: | 10.1093/rheumatology/keag521 |